Company Analysis
Sign in

ProQR Therapeutics N.V. (PRQR)

Nasdaq: PRQR · Pharmaceutical Preparations · Leiden, NL · filing with the SEC since 2014
Full chart Alerts Compare
Grade5.2
◀ Past 6.6● Present 4.7▶ Future 4.8
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue€15.9M-15.9%
Net income-€42.2M-51.9%
Earnings per share€-0.40-25.0%
Operating cash flow-€52.8M-45.1%
Cash€92.4M-38.1%
Debt€4.9M+6.3%
Shareholders’ equity€49.4M-44.2%
Shares, diluted105.3M+22.4%
Return on equity-85.4%
The recordfrom its filings
Filings in 202652
Newest filingNov 12 · 6-K
Annual reportMar 12, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$1.3M
Patents granted24
Filer categoryAccelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in EUR. Nothing here is a forecast.

News

Aug 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Jul 29, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton PRQR · research, not advice